UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials

Annals of oncology, 2015-09, Vol.26 (9), p.1808-1812

2015

Volltextzugriff (PDF)

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Annals of oncology, 2017-07, Vol.28 (7), p.1605-1611

2017

Volltextzugriff (PDF)

Phase I–II trial designs: how early should efficacy guide the dose recommendation process?

Annals of oncology, 2018-03, Vol.29 (3), p.540-541

2018

Volltextzugriff (PDF)

SP001 Biostatistical challenges for the design of biology-driven trials

European journal of cancer (1990), 2013-11, Vol.49, p.S1-S1

Paoletti, X

2013

Volltextzugriff (PDF)

Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program)

European heart journal, 2013-01, Vol.34 (2), p.112-120

2013

Volltextzugriff (PDF)

A comparison of model choices for the continual reassessment method in phase I cancer trials

Statistics in medicine, 2009-10, Vol.28 (24), p.3012-3028

2009

Volltextzugriff (PDF)

Designs of drug-combination phase I trials in oncology: a systematic review of the literature

Annals of oncology, 2015-04, Vol.26 (4), p.669-674

2015

Volltextzugriff (PDF)

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Annals of oncology, 2017-03, Vol.28 (3), p.590-596

2017

Volltextzugriff (PDF)

Designs of preoperative biomarkers trials in oncology: a systematic review of the literature

Annals of oncology, 2015-12, Vol.26 (12), p.2419-2428

2015

Volltextzugriff (PDF)

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

British journal of cancer, 2014-07, Vol.111 (1), p.17-24

2014

Volltextzugriff (PDF)

REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours

Annals of oncology, 2014-12, Vol.25 (12), p.2351-2356

2014

Volltextzugriff (PDF)

Consequences of running more operating theatres than anaesthetists to staff them: a stochastic simulation study

British journal of anaesthesia : BJA, 2007-04, Vol.98 (4), p.462-469

2007

Volltextzugriff (PDF)

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

Annals of oncology, 2019-02, Vol.30 Suppl 1, p.i5

2019

Volltextzugriff (PDF)

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

British journal of cancer, 2012-02, Vol.106 (5), p.854-857

2012

Volltextzugriff (PDF)

Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients

ESMO open, 2022-02, Vol.7 (1), p.100366-100366, Article 100366

2022

Volltextzugriff (PDF)

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials

Annals of oncology, 2008-06, Vol.19 (6), p.1117-1126

2008

Volltextzugriff (PDF)

Patients’ perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study

European journal of cancer care, 2017-11, Vol.26 (6), p.e12596-n/a

2017

Volltextzugriff (PDF)

Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study

Human reproduction (Oxford), 2004-10, Vol.19 (10), p.2216-2221

2004

Volltextzugriff (PDF)

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials

Annals of oncology, 2015-02, Vol.26 (2), p.422-428

2015

Volltextzugriff (PDF)

349 Impact of the re-definition of dose-limiting toxicities (DLTs) according to recent recommendations on the DLT rate in phase 1 trials of molecularly targeted agents

European journal of cancer (1990), 2015-09, Vol.51, p.S70-S70

2015

Volltextzugriff (PDF)

901 Reporting adverse events (AEs) in cancer surgery randomized trial: A systemic analysis of published trials in oesogastric (OG) and gynecological (GY) cancer patients

European journal of cancer (1990), 2015-09, Vol.51, p.S140-S140

2015

Volltextzugriff (PDF)

O3-1.2 How to perform a sensitivity analysis exploring the impact of missing not at random data with the R® software

Journal of epidemiology and community health (1979), 2011-08, Vol.65 (Suppl 1), p.A31-A31

2011

Volltextzugriff (PDF)

421 INVITED Tackling Futility With Adaptive Designs

European journal of cancer (1990), 2011, Vol.47, p.S92-S92

2011

Volltextzugriff (PDF)

A proposal for a new PhD level curriculum on quantitative methods for drug development

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2018-09, Vol.17 (5), p.593-606

2018

Volltextzugriff (PDF)

REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours

Annals of oncology, 2015-11, Vol.26 (11), p.2359-2359

2015

Volltextzugriff (PDF)

1 – 25 von 198

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(173)
Mit Volltextzugriff
(164)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Phase I–II trial designs: how early should efficacy guide the dose recommendation process?

SP001 Biostatistical challenges for the design of biology-driven trials

Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program)

A comparison of model choices for the continual reassessment method in phase I cancer trials

Designs of drug-combination phase I trials in oncology: a systematic review of the literature

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Designs of preoperative biomarkers trials in oncology: a systematic review of the literature

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours

Consequences of running more operating theatres than anaesthetists to staff them: a stochastic simulation study

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials

Patients’ perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study

Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials

349 Impact of the re-definition of dose-limiting toxicities (DLTs) according to recent recommendations on the DLT rate in phase 1 trials of molecularly targeted agents

901 Reporting adverse events (AEs) in cancer surgery randomized trial: A systemic analysis of published trials in oesogastric (OG) and gynecological (GY) cancer patients

O3-1.2 How to perform a sensitivity analysis exploring the impact of missing not at random data with the R® software

421 INVITED Tackling Futility With Adaptive Designs

A proposal for a new PhD level curriculum on quantitative methods for drug development

REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours

Suchergebnisse filtern